Hengrui Liu
Medical Research   Â, Oncology   Â, Toxicology (General)    Cancer Medical Research Oncology Toxicology (General) Cancer Cells and Metastasis Colorectal Cancer Treatments and Studies Breast Cancer Treatment Studies Cancer Research

Bio

Dr. Hengrui Liu is a researcher affiliated with Stony Brook University Hospital and a Visiting Scientist at the University of Cambridge, Department of Oncology. His research primarily explores cancer biology, focusing on ion channels like TRPM7 and their role in breast cancer, as well as the effects of local anesthetics on cancer stemness. He has received awards such as the AstraZeneca Cambridge Ion Channel Forum Poster Prize and the China Scholarship Council's Award for Outstanding Self-financed Student Abroad.

Experience

Visiting Scientist

2024 - Present • Department of Oncology

Stony Brook Medicine

Research Scholar

2017 - 2019 • Department of Anesthesiology

0 - 0

Grants and Awards

DISTINCTION

Cambridge Ion Channel Forum Poster Prize First Prize

AstraZeneca

2022
DISTINCTION

Award for Outstanding Self-financed Student Abroad

China Scholarship Council

2021
DISTINCTION

Academic Progress Award

Anesthesia and Cancer Laboratory, Stony Brook Medicine

2018
GRANT

Charles Slater Fund

University of Cambridge

2025
Show all 4 grants

Research

A Prospective for the Potential Effect of Local Anesthetics on Stem-Like Cells in Colon Cancer

Article March 17, 2020

Colorectal cancer is the third most prevalent cancer and the second most frequent cause of cancer-related death in the world. Surgical resection of the primary tumor is the central aspect of the current multiple modes of treatment and has been associated with better prognosis. The process of surgery, including anesthetic regimens, has increasingly been recognized to affect colon cancer recurrence and metastasis. Both retrospective clinical studies and laboratory studies have reported that colon cancer cells are inhibited by some local anesthetics. However, the application of local anesthetics in colon cancer treatment is limited by our understanding of the mechanisms underlying their effects on cancer biology.